Valuation: Astellas Pharma Inc.

Market Cap 4,030B 25.39B 22.73B 21.18B 19.22B 36.24B 2,427B 36.47B 255B 99.66B 1,252B 95.36B 93.25B P/E 2027 *
10.4x
P/E 2028 * 11x
Enterprise Value 3,971B 25.01B 22.39B 20.87B 18.93B 35.71B 2,391B 35.93B 251B 98.2B 1,234B 93.96B 91.88B EV / Sales 2027 *
1.68x
EV / Sales 2028 * 1.61x
Free-Float
98.92%
Yield 2027 *
3.57%
Yield 2028 * 3.7%
1 day-0.02%
1 week+0.11%
Current month-3.15%
1 month+0.31%
3 months+4.93%
6 months-13.79%
Current year+7.38%
1 week 2,216
Extreme 2216
2,288
1 month 2,216
Extreme 2216
2,413
Current year 2,041
Extreme 2041
2,717
1 year 1,557.5
Extreme 1557.5
2,717
3 years 1,243.5
Extreme 1243.5
2,717
5 years 1,243.5
Extreme 1243.5
2,717
10 years 1,243.5
Extreme 1243.5
2,717
Manager TitleAgeSince
Chief Executive Officer 64 10/02/2023
Director of Finance/CFO 55 01/11/2023
Compliance Officer - 01/04/2025
Director TitleAgeSince
Chairman 66 10/02/2023
Director/Board Member 64 01/06/2019
Director/Board Member 59 01/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
-0.02%+0.11%+38.65%+10.20% 25.45B
+0.28%+3.46%+44.33%+93.71% 1,051B
+0.88%+4.27%+38.15%+68.70% 630B
+1.68%+5.78%+22.07%+89.56% 489B
-0.10%+4.24%+69.72%+40.41% 359B
+0.61%+4.14%+24.05%+41.70% 344B
+0.72%+3.11%+14.29%+33.76% 272B
+0.23%+1.31%-5.91%+9.89% 246B
+0.65%+3.62%+42.81%+46.50% 224B
-0.49%+4.01%+27.26%+95.97% 187B
Average +0.26%+2.58%+31.54%+53.04% 382.92B
Weighted average by Cap. +0.37%+2.91%+34.70%+66.52%

Financials

2027 *2028 *
Net sales 2,364B 14.89B 13.33B 12.43B 11.27B 21.26B 1,423B 21.39B 149B 58.46B 735B 55.93B 54.69B 2,206B 13.9B 12.44B 11.6B 10.52B 19.84B 1,328B 19.96B 139B 54.56B 686B 52.2B 51.05B
Net income 373B 2.35B 2.1B 1.96B 1.78B 3.35B 224B 3.37B 23.54B 9.21B 116B 8.82B 8.62B 349B 2.2B 1.97B 1.84B 1.66B 3.14B 210B 3.16B 22.05B 8.63B 108B 8.26B 8.08B
Net Debt -59.18B -373M -334M -311M -282M -532M -35.64B -536M -3.74B -1.46B -18.39B -1.4B -1.37B -481B -3.03B -2.71B -2.53B -2.29B -4.32B -289B -4.35B -30.37B -11.89B -149B -11.37B -11.12B
Projected Income Statement - Annual - Astellas Pharma Inc.
Logo Astellas Pharma Inc.
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Employees
14,099
Date Price Change Volume
09/10/26 ¥2,247.50 -0.02% 5,898,400
08/10/26 ¥2,248.00 -0.33% 5,458,800
07/10/26 ¥2,255.50 +0.53% 5,853,100
06/10/26 ¥2,243.50 +0.38% 5,031,100
05/10/26 ¥2,235.00 -0.45% 4,295,600
Trader
Investor
Global
Quality
ESG MSCI
AA
Ratings Surperformance© - Astellas Pharma Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
2,247.50JPY
Average target price
2,529.29JPY
Spread / Average Target
+12.54%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Astellas Pharma Inc.
  1. Stock Market
  2. Stocks
  3. 4503 Stock